Apellis Pharmaceuticals, Inc.


SKU: APLS-1 Category:


Apellis Pharmaceuticals, Inc.: Strategic Marketing and Direct-to-Consumer (DTC) Campaigns Changing The Game!


Apellis Pharmaceuticals experienced a strong start to the first quarter of 2024, showing significant growth particularly through its product SYFOVRE, which demonstrated impressive market uptake and robust sales growth. SYFOVRE generated $137 million in net sales for the quarter, marking a 20% increase from the previous quarter. This increase predominantly stemmed from accelerated demand as the product solidified its position in the market. Furthermore, SYFOVRE’s performance in its first year post-launch, generating over $400 million, exceeded expectations significantly, highlighting its market acceptability and potential for long-term growth.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!